Anticentromere antibody — clinical associations
✍ Scribed by P. Caramaschi; T. Manzo; D. Biasi; A. Carletto; F. Poli; L. M. Bambara
- Publisher
- Springer
- Year
- 1995
- Tongue
- English
- Weight
- 303 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0172-8172
No coin nor oath required. For personal study only.
✦ Synopsis
The objective of this study was to determine the clinical features of 44 patients with anticentromere antibody (ACA) positivity. We undertook a retrospective review of 44 ACA-positive patients (1 male and 43 females with a mean +/- SD age of 53.6 +/- 12.2 years). There were 25 patients with limited systemic sclerosis, 12 with Raynaud's disease, 2 with Sjögren's syndrome, 2 with systemic lupus erythematosus and 3 with polyarthritis. ACA was more frequently found in patients affected by limited systemic sclerosis with mild visceral involvement and in patients with Raynaud's disease. Moreover, ACA was detected in other connective tissue diseases that were characterized by an atypical autoantibody profile.
📜 SIMILAR VOLUMES
Anticentromere antibodies (ACA) and anti-topoisomerase I (anti-top0 I) were assayed in serum samples from 355 patients: 89 with proximal scleroderma; 54 with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility , sclerodactyly , telangiectasias), without proximal scleroderma; 154
The presence of antibody to the chromosomal centromere appears to be associated with a subset of patients with the limited CREST form of scleroderma. To further define the prognostic value of this autoantibody, 27 patients, who were identified as having anticentromere antibody by screening antinucle